SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-001615
Filing Date
2022-02-22
Accepted
2022-02-22 16:45:24
Documents
14
Period of Report
2022-02-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20220218x8k.htm   iXBRL 8-K 40495
2 EX-99.1 sgtx-20220218xex99d1.htm EX-99.1 11061
3 GRAPHIC sgtx-20220218xex99d1001.jpg GRAPHIC 5781
  Complete submission text file 0001558370-22-001615.txt   189636

Data Files

Seq Description Document Type Size
4 EX-101.SCH sgtx-20220218.xsd EX-101.SCH 3031
5 EX-101.LAB sgtx-20220218_lab.xml EX-101.LAB 16735
6 EX-101.PRE sgtx-20220218_pre.xml EX-101.PRE 10609
8 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220218x8k_htm.xml XML 5053
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 22658892
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences